Baxter (BAX) Tops Q3 EPS by 2c; offers guidance

Baxter (NYSE: BAX) reported Q3 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $3.85 billion versus the consensus estimate of $3.85 billion.

GUIDANCE:

Baxter sees Q4 2024 EPS of $0.77-$0.81, versus the consensus of $0.85.

Baxter sees FY2024 EPS of $2.90-$2.94, versus the consensus of $2.95.

For earnings history and earnings-related data on Baxter (BAX) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Boeing names Ryan Shedd as new SVP and controller
• Nuvectis Pharma (NVCT) files $200M mixed shelf